<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001756</url>
  </required_header>
  <id_info>
    <org_study_id>980027</org_study_id>
    <secondary_id>98-I-0027</secondary_id>
    <nct_id>NCT00001756</nct_id>
  </id_info>
  <brief_title>Study of Mast Cell Precursors</brief_title>
  <official_title>The Characterization of CD34+ Derived Mast Cell Precursors Mobilized by Administration of Granulocyte Colony Stimulating Factor and Plerixafor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will investigate mast cell precursors that circulate in the blood. In a group of
      diseases collectively known as mastocytosis, mast cells accumulate in abnormal amounts in the
      skin, lymphoid tissues, bone marrow, liver and spleen. Some forms of mastocytosis have a
      generally good prognosis; for others, the prognosis is poorer. There is no known cure for any
      form of the disease. A better understanding of mast cells and how they respond to certain
      substances may provide insights that will lead to effective treatments for mastocytosis.

      Patients with systemic mastocytosis and normal healthy volunteers between the ages of 20 and
      60 may be eligible for this 8-day study. Participants will undergo the following procedures:

        -  Day 1 Medical history, physical examination, and blood tests to assess general health
           status

        -  Days 2 through 6 Daily injections under the skin of G-CSF a hormone that stimulates
           white blood cell production

        -  Day 7 Leukapheresis a procedure for collecting large numbers of white blood cells. In
           leukapheresis, blood is drawn through a needle placed in an arm and channeled into a
           cell separator machine. The white cells are collected and the rest of the blood is
           returned to the body through a needle in the other arm. The procedure takes up to 3
           hours.

        -  Days 7 and 8 Blood draw (about 1 teaspoon) to monitor white blood cell counts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral
      blood of healthy volunteers and patients with systemic mastocytosis or other related
      allergic, hematological, and immunological conditions by leukapheresis for culture and
      characterization of mast cell progenitor cells and their response to various cytokines and
      anti-mitotic agents. Healthy volunteers and patients will be adults of both sexes from 18 to
      70 years of age. Granulocyte colony stimulating factor (G-CSF) will be administered to
      healthy volunteers at dose of 10 mcg/kg/day as a subcutaneous dose daily for 5 days not to
      exceed 960mcg. Patients will receive Plerixafor at a dose of 0.24 mg/kg as a single
      subcutaneous dose not to exceed 24mg the night before leukapheresis as a mobilizing agent for
      CD34+ cells. In identified patients where leukapheresis yield is considered adequate without
      stimulation by the principal investigator, leukapheresis may proceed without stimulation.
      Healthy volunteers will undergo a single leukapheresis at day 7, and patients will undergo a
      single leukapheresis at day 3 or 4. This is not a therapeutic protocol and does not involve
      reinfusion of any manipulated cells, viruses or DNA constructs back into human subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 12, 1997</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. Use of G-CSF administration in healthy volunteers to mobilize and enhance CD34+ hematopoietic progenitor cell numbers into the peripheral blood in order to culture and characterize human mast cells, study and characterize CD34+ -derived human...</measure>
    <time_frame>Ongoing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Use of Plerixafor administration in patients with systemic mastocytosis and other related allergic, hematological and immunological conditions to mobilize and enhance CD34+ cells into the peripheral blood to culture and learn how mast cells c...</measure>
    <time_frame>Ongoing</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Normal Physiology</condition>
  <condition>Systemic Mastocytosis</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  SUBJECT INCLUSION CRITERIA:

        Healthy Volunteers must:

          1. Be 18-70 years of age

          2. Be healthy

          3. Have adequate peripheral venous access

          4. Have normal renal function (creatinine less than or equal to 1.5mg/dL; less than or
             equal to 1 plus proteinuria)

          5. Have normal hepatic function (bilirubin less than or equal to 1.5 mg/dL)

          6. Have normal hematologic function (WBC greater than or equal to 3000/mm(3);
             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to
             175,000; hemoglobin greater than or equal to 12.5 g/dL)

        Patients must:

          1. Be 18-70 years of age

          2. Have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis
             (applicable to systemic mastocytosis patients only) or other allergic, hematologic, or
             immunologic condition

          3. Have adequate peripheral venous access or be willing to have a central line placed.

          4. First be admitted as inpatients under an existing NIH protocol

          5. Have preserved renal function (creatinine less than or equal to 2 mg/dL; less than or
             equal to 2 plus proteinuria)

          6. Have preserved hepatic function (bilirubin less than or equal to 1.5 mg/dL)

          7. Have preserved hematologic function (WBC greater than or equal to 3000/mm(3);
             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to
             175,000; hemoglobin greater than or equal to 12.5 g/dL)

        All female subjects of childbearing potential:

          1. May be enrolled if using effective contraception

          2. Have a negative serum or urine pregnancy test determined before beginning Plerixafor
             or G-CSF administration

        SUBJECT EXCLUSION CRITERIA:

        All subjects must not meet any of the following criteria:

        Healthy volunteers and patients must not:

          1. Have active bacterial, fungal or viral infections

          2. Have viral screens positive for HIV or hepatitis B or C

          3. Be pregnant or lactating

          4. Have a history of autoimmune disease such as rheumatoid arthritis, vasculitis,
             pyoderma gangrenosum or similar disorder

          5. Have any condition, which in the judgment of the investigator, might place the subject
             at undue risk

        Healthy Volunteers with any of the following will be excluded:

          1. Splenomegaly, pulmonary fibrosis and other related conditions

          2. Use of any investigative drugs within the past 12 months

          3. Have a significant coagulation disorder

        Systemic Mastocytosis and Mast Cell Related Condition Patients with any of the following
        will be excluded:

          1. Patients taking any other growth factors, cytokines or investigative drugs

          2. Patients who are hemodynamically unstable (blood pressure systolic of lower than 105
             or diastolic lower than 65)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirsh D Komarow, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin R. Eisch, R.N.</last_name>
    <phone>(301) 443-1720</phone>
    <email>eischar@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hirsh D Komarow, M.D.</last_name>
    <phone>(301) 594-2197</phone>
    <email>komarowh@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1998-I-0027.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Schwinger W, Mache C, Urban C, Beaufort F, TÃ¶glhofer W. Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers. Bone Marrow Transplant. 1993 Jun;11(6):489-92.</citation>
    <PMID>8334430</PMID>
  </reference>
  <reference>
    <citation>Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991 Mar;96(3 Suppl):2S-4S; discussion 4S, 60S-65S. Review.</citation>
    <PMID>16799601</PMID>
  </reference>
  <verification_date>August 8, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukapheresis</keyword>
  <keyword>Mastocytosis</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Mast Cells</keyword>
  <keyword>Normal Volunteer</keyword>
  <keyword>Systemic Mastocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

